In a systematic review of studies regarding breast cancer, van de Ven et al. demonstrated that the statuses of HER2 and other hormonal receptors changed in 43–51% of patients who received T-mab-containing therapy [3]. This evidence concerns the gene ERBB2 and breast carcinoma.